Manifestações neurológicas da COVID-19, doenças cerebrovasculares, cefaleias e distúrbios do movimento foram temas de importantes publicações no último ano. Veja...
2020 In Review: o que mudou na urologia?
Escrito por: MDHealth em 15 de janeiro de 2021
11 min de leitura
Referências
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A. Survival with olaparib in metastatic castration-resistant prostate cancer. New England Journal of Medicine. 2020 Dec 10;383(24):2345-57.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer
Donskov F, Motzer RJ, Voog, et al. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. European Journal of Cancer. DOI: 10.1016/j.ejca.2019.10.032.
Plimack ER, Rini BI, Stus V, Gafanov R, Waddell T, Nosov D, Pouliot F, Soulieres D, Melichar B, Vynnychenko I, Azevedo SJ. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/robotic-prostatectomy
